anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
M.R2k/b mice are identical to the MA/My parent strain aside from a 5.58-Mb C57L-derived region on chromosome 17 (Cmv5s) that causes increased susceptibility to acute murine CMV (MCMV) infection and the development of significant spleen tissue damage. Spleen pathology begins at the marginal zone (MZ), apparent by 2 d postinfection (dpi), and progresses throughout the red pulp by 4 dpi. To better understand how M.R2k/b mice respond to infection and how Cmv5s contributes to tissue damage in the spleen, we assessed the regulation of myeloid cells and inflammation during acute MCMV infection in MA/My and M.R2k/b mice. We found that Cmv5s drove increased neutrophil accumulation and cell death at the MZ, which corresponded with evidence of localized oxidative stress and increased overall spleen IL-6 and TGF-β1 early during infection. Further assessment of MCMV infection dynamics at the early MZ revealed infected SIGNR1+ MZ macrophages as the first apparent cell type lost during infection in these mice and the likely target of early neutrophil recruitment. Spleen macrophages were also identified as the mediators of differential spleen IL-6 and TGF-β1 between MA/My and M.R2k/b mice. Interrogation of MCMV progression past 2 dpi revealed substantial M.R2k/b F480+ red pulp macrophage loss along with buildup of oxidative stress and MZ macrophage debris that was not neutrophil dependent. Together we identify Cmv5s-driven macrophage loss and inflammation during acute MCMV infection corresponding with the spatial and temporal development of spleen tissue damage.
This arm part is also to enroll 40 gastroparetic subjects to undergo blood draw before, after transcutaneous stimulation of the auricular branch of the vagus nerve, and a third draw after a period of no stimulation. Blood Draws are to obtain levels of Insulin, Glucose, and C-peptide for: baseline, Experimental and Recovery.
Glycosaminoglycans are complex carbohydrates used as nutraceuticals for diverse applications. We studied the potential of the glycosaminoglycan dermatan sulfate (DS) to counteract the development of diet-induced obesity (DIO) using obesity-prone mice fed a high-fat diet (HFD) as a model. Oral DS supplementation protected the animals against HFD-induced increases in whole-body adiposity, visceral fat mass, adipocyte size, blood glucose levels, insulin resistance, and pro-inflammatory lipids levels in brown adipose tissue (BAT) and the liver, where it largely counteracted the HFD-induced changes in the nonpolar metabolome. Protection against DIO in the DS-supplemented mice occurred despite higher energy intake and appeared to be associated with increased energy expenditure, higher uncoupling protein 1 expression in BAT, decreased BAT "whitening," and an enhanced channeling of fuel substrates toward skeletal muscle. This work is the first preclinical study to examine the anti-obesity activity of DS tested individually in vivo. The results support possible uses of DS as an active component in functional foods/supplements to manage obesity and associated metabolic diseases.
This is a randomized (patients are assigned by chance to a treatment group), double-blind (neither the patient or the physician know which treatment is being received by the patient), placebo-controlled, multicenter study of epoetin alfa in anemic patients who are diagnosed with myelodysplastic syndromes (MDS) according to protocol-specified criteria. Patients meeting entry criteria for the study will be randomly assigned to receive epoetin alfa 40,000 IU or 80,000 IU or a matching volume of placebo administered by subcutaneous (under the skin) injection once every week. Doses of study drug will be withheld, decreased, or increased on the basis of weekly hemoglobin concentrations monitored in patients and predefined dose adjustment guidelines. An Independent Data Monitoring Committee (IDMC) will periodically review study data and for the assessment of disease progression, an independent central reviewer will review bone marrow specimens and peripheral blood counts. Safety will be monitored throughout the study at predetermined intervals and as clinically indicated by physical examination, laboratory tests and evaluation of adverse events. Patients in the Treatment Phase will be randomly assigned to receive once weekly epoetin alfa subcutaneously (SC) at a dose of 40,000 IU (1 mL) or 80,000 IU (2ML) or matching volume of placebo (1 mL or 2 mL) once every week for 48 weeks. Patients may continue to receive double-blinded treatment after 48-weeks.
BACKGROUND: Information on the public's preferences for current public health and social measures (PHSMs) and people's mental health under PHSMs is insufficient.
OBJECTIVE: This study aimed to quantify the public's preferences for varied PHSMs and measure the level of pandemic fatigue in the COVID-19 normalization stage in China.
METHODS: A nationwide cross-sectional study with a discrete choice experiment and psychometric scales was conducted to assess public preferences for and attitudes toward PHSMs, using the quota sampling method. The COVID-19 Pandemic Fatigue Scale (CPFS) was used to screen fatigue levels among respondents. The multinomial logit model, latent class model, and Mann-Whitney test were used for statistical analysis. We also conducted subgroup analysis based on sex, age, monthly income, mental health status, and pandemic fatigue status.
RESULTS: A total of 689 respondents across China completed the survey. The discrete choice experiment revealed that respondents attached the greatest importance to the risk of COVID-19 infection within 3 months (45.53%), followed by loss of income within 3 months (30.69%). Vulnerable populations (low-income populations and elderly people) were more sensitive to the risk of infection, while younger respondents were more sensitive to income loss and preferred nonsuspension of social places and transportation. Migrants and those with pandemic fatigue had less acceptance of the mandatory booster vaccination and suspension of transportation. Additionally, a higher pandemic fatigue level was observed in female respondents, younger respondents, migrants, and relatively lower-income respondents (CPFS correlation with age: r=-0.274, P<.001; correlation with monthly income: r=-0.25, P<.001). Mandatory booster COVID-19 vaccination was also not preferred by respondents with a higher level of pandemic fatigue, while universal COVID-19 booster vaccination was preferred by respondents with a lower level of pandemic fatigue.
CONCLUSIONS: Pandemic fatigue is widely prevalent in respondents across China, and respondents desired the resumption of normal social life while being confronted with the fear of COVID-19 infection in the normalization stage of COVID-19 in China. During future pandemics, the mental burden and adherence of residents should be considered for the proper implementation of PHSMs.
It's a randomised crossover clinical trial. Subjects: chronic hemodialysis patients. All subjects will be randomised to 2 groups. Subjects in first group will receive 4 weeks transdermal clonidine plus regular antihypertensive agents treatments first, 2weeks wash-out then and 4 weeks antihypertensive agents without transdermal clonidine. The other group will receive 4 weeks antihypertensive agents without transdermal clonidine first, 2weeks wash-out then and 4 weeks transdermal clonidine plus regular antihypertensive agents treatments. Ambulatory blood pressure, echocardiography, and biochemistry will be detected.
Study design:

Two centers specializing in diabetic foot management (located in Sesto S. Giovanni and Milan, Italy) participated to this open, randomized clinical trial. The ethics-committee approved the study on January 10th, 2008. Enrollment of consecutive patients began February 2008 and ended March 2009. Eligible patients were fully informed of the study aim and procedures and written consent was obtained prior to study participation. Patients were then randomly assigned to one of the two treatment groups by opening randomization codebreak envelopes containing one of the two options. Separate randomization was performed for each center, and a copy of all randomization envelopes was kept at the statistical department of the Multimedica center. The two arms were composed of patients managed with non-removable fiberglass off-bearing cast (TCC group) and patients offloaded with the Stabil-D® (Podartis srl, Montebelluna, Treviso, Italy) walker cast (Stabil-D group).
A cosmetic and/or dermatological formulation comprises a combination for topical application of at least one anionic polyamino acid matrix (a), and at least one polysaccharide (b). ACTIVITY : Dermatological. A formulation comprising gamma -polyglutamic acid, polysaccharide, trimethylglycine, urea, potassium lactate and water was prepared. To determine the in vivo sorption-desorption properties of the active ingredient combination, the formulation was applied twice daily by 3 subjects to the forearm for 3 weeks. After 3 weeks, the hydration state of the skin was firstly determined. A wet paper towel was then placed onto the forearm (contact time: 2 minutes) in order to saturate the upper layers of the skin with moisture. The skin surface was then patted with a dry paper towel and the skin moisture was measured. The skin moisture was then monitored at regular intervals. The result showed that the skin which had been treated with the active ingredient combination firstly absorbed more water and secondly also binded this water more strongly and for a longer period of time. MECHANISM OF ACTION : None given.
The present invention relates to inhibitors of post-proline cleaving enzymes, such as inhibitors of dipeptidyl peptidase IV, as well as pharmaceutical compositions thereof, and methods for using such inhibitors. In particular, the inhibitors of the present invention are improved over those in the prior art by selection of particular classes of sidechains in the P1 and/or P2 position of the inhibitor. The compounds of the present invention can have a better therapeutic index, owing in part to reduced toxicity and/or improved specificity for the targeted protease.; The present invention relates to inhibitors of post-proline cleaving enzymes, such as inhibitors of dipeptidyl peptidase IV, as well as pharmaceutical compositions thereof, and methods for using such inhibitors. In particular, the inhibitors of the present invention are improved over those in the prior art by selection of particular classes of sidechains in the P1 and/or P2 position of the inhibitor. The compounds of the present invention can have a better therapeutic index, owing in part to reduced toxicity and/or improved specificity for the targeted protease.
Intraocular injection of adeno-associated viral (AAV) vectors has been an evident route for delivering gene drugs into the retina. Currently, the vectors need to be injected into the subretinal space in order to provide gene delivery to cones. In this approach, gene delivery is limited to cells that contact the local "bleb" of injected fluid. Furthermore, retinal detachment that occurs during subretinal injections is a concern in eyes with retinal degeneration. Here, the inventors establish several new vector-promoter combinations to overcome the limitations associated with AAV-mediated cone transduction in the fovea with supporting studies in mouse models, human induced pluripotent stem cell-derived organoids, post-mortem human retinal explants and living macaques. They show that an AAV9 variant provides efficient foveal cone transduction when injected into the subretinal space several millimeters away from the fovea, without detaching this delicate region. The delivery modality relies on a cone-specific promoter and result in high-level transgene expression compatible with optogenetic vision restoration. Accordingly, the present invention relates to method of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising subretinal delivery of a therapeutically effective amount of a recombinant AAV9-derived vector comprising a VP1 capsid protein as set forth in SEQ ID NO: 11 and the polynucleotide of interest under the control of the pR1.7 promoter as set forth in SEQ ID NO: 12.25
Loss of select neuronal populations such as midbrain dopamine (DA) neurons is a pathological hallmark of Parkinson's disease (PD). The small neuronal protein α-synuclein has been related both genetically and neuropathologically to PD, yet how and if it contributes to selective vulnerability remains elusive. Here, we describe the generation of a novel adeno-associated viral vector (AAV) for Cre-dependent overexpression of wild-type human α-synuclein. Our strategy allows us to restrict α-synuclein to select neuronal populations and hence investigate the cell-autonomous effects of elevated α-synuclein in genetically-defined cell types. Since DA neurons in the substantia nigra pars compacta (SNc) are particularly vulnerable in PD, we investigated in more detail the effects of increased α-synuclein in these cells. AAV-mediated overexpression of wildtype human α-synuclein in SNc DA neurons increased the levels of α-synuclein within these cells and augmented phosphorylation of α-synuclein at serine-129, which is considered a pathological feature of PD and other synucleinopathies. However, despite abundant α-synuclein overexpression and hyperphosphorylation we did not observe any dopaminergic neurodegeneration up to 90 days post virus infusion. In contrast, we noticed that overexpression of α-synuclein resulted in increased locomotor activity and elevated striatal DA levels suggesting that α-synuclein enhanced dopaminergic activity. We therefore conclude that cell-autonomous effects of elevated α-synuclein are not sufficient to trigger acute dopaminergic neurodegeneration.
The invention discloses an avian adenovirus recombinant protein targeting DCs and application thereof in preparation of avian adenovirus subunit vaccines, belonging to the technical field of biology. The avian adenovirus recombinant protein of the targeting DCs is obtained by fusing avian adenovirus fiber protein and a targeting peptide SP sequence of chicken bone marrow-derived dendritic cells, and then inserting the fiber protein sequence fused with the targeting peptide sequence between the N end and the C end of a salmonella typhimurium flagellin B subunit by using a flexible Linker. Wherein the avian adenovirus fiber protein is avian adenovirus serum type 4, 8b or 11 fiber protein or fusion protein containing key epitope of the at least two serotypes of avian adenovirus fiber protein. Preferably, the amino acid sequence of the recombinant protein of the avian adenovirus targeting DCs is shown in any one of SEQ ID NO. 1-4. The invention provides an effective technical means for preventing the mixed infection of the avian adenovirus, in particular to the multi-serotype avian adenovirus.
OBJECTIVE: The primary objective of this study was to evaluate oncologic outcomes of all published cases of supracricoid partial laryngectomy (SCPL) performed in the United States. The secondary objective was to assess the functional outcomes associated with this procedure.
REVIEW METHODS: A systematic review of PubMed, SCOPUS, and Embase for all English-language studies pertaining to SCPL performed in the United States was conducted until August 2021. Primary outcomes included disease-specific survival (DSS), overall survival, and local recurrence rate. Secondary outcomes included larynx preservation rate, gastrostromy tube dependency, days to gastrostomy tube removal, decannulation rate, and days to decannulation.
RESULTS: A total of six studies were included in the analysis. A total of 113 patients (58.5%) underwent SCPL surgery as a primary treatment method whereas 80 patients (41.5%) underwent SCPL as salvage surgery. The 5-year DSS rates were 87.8% and 100% for primary and salvage procedures, respectively. Approximately 10.3% of patients undergoing a salvage SCPL procedure experienced a local recurrence whereas only 1.85% of primary SCPL procedures resulted in local recurrence. The rates of decannulation following primary and salvage SCPL were 92.7% and 88.1%, respectively. With regard to swallowing, primary and salvage SCPL procedures demonstrated comparably low postoperative gastrostomy tube dependency rates of 3.66% and 4.76%, respectively.
CONCLUSIONS: SCPL performed in the United States is an effective surgical technique that produces excellent outcomes in qualifying patients, thus validating its viability as an organ-preserving surgical alternative. Laryngoscope, 134:3003-3011, 2024.
This Phase I study is a randomized, double-blind, placebo-controlled evaluation of the safety and pharmacokinetics of escalating single oral doses of oxfendazole (0.5 to 60 mg/kg) in healthy volunteers. Up to 70 healthy males and females (non-chldbearing potential), ages 18-45 volunteers recruited from one site will participate in this study. The study duration is approximately 18 months with subject participation of 2 weeks. The primary objective assess the safety and tolerability of oxfendazole in healthy adults. The secondary objectives assess the pharmacokinetic profile of oxfendazole and assess the metabolism of oxfendazole. Two sentinel subjects will receive the study product (1 drug/1 placebo) in each group and be monitored 48 hours for adverse events prior to completing enrollment of the remaining 8 subjects in the group.
The invention relates to an alpha-glycosidase depressant as prunella spike extract, which is water extract and fluid extract. The making method comprises the following steps: getting water extract through cold soaking and hot extracting prunella spike; thickening supernatant fluid to get the fluid extract after taking part water extract to alcoholic sink. The invention is characterized by the following: adding 5 different densities at 31. 25mg/ml, 62. 5mg/ml, 125 mg/ml, 250mg/ml and 500mg/ml of water extract equaling to crude drug and basing 5mg/ml Baitangping as positive contrast into measuring system respectively, the test shows that inhibiting rates of Baitangping to alpha-glycosidase is 73. 9% and to water extract is 84. 6-96. 2%; adding 5 different densities with 12. 5mg/ml, 25mg/ml,50mg/ml, 100mg/ml and 200mg/ml of fluid extract into the measuring system respectively, the result shows that inhibiting rate achieves 93. 5-98. 4%; including flavonol glycosides compound through attesting extract and perhaps related to inhibit activity of alpha-glycosidase.
This invention provides ocular formulations comprising an ocular drug and a carboxylic acid in an amount sufficient to maintain the pH of the formulation from about 4.5 to about 7.5. The ocular drug may be a dopamine antagonist and the acid may be lactic acid, citric acid or tartaric acid. In some aspects, the pH of the formulation is about 5.5. The ocular formulations of this invention provide enhanced bioavailability which results in increased drug concentrations across the cornea and in the eye ball, i.e., aqueous humor and intraocular organs and chambers. Moreover, the present formulations are non-irritating when applied topically and have a shelf-life of at least fourteen days at 25 °C. Methods are also provided to increase ocular blood flow by using present ocular formulations comprising dopamine antagonists or other drugs for the prevention and treatment of ocular hypertension, glaucoma, ischemic retinopathy and age-related macular degeneration (AMD).
The invention discloses a traditional Chinese medicine composition for treating chronic bronchitis. The traditional Chinese medicine composition for treating the chronic bronchitis is prepared from argyreia acuta lour, dried spiced cabbage, heliotropium indicum, puffball, roots of hupeh euphorbia, fruits of Chinese mahonia, pinellia ternate, ligustrum barks, blackberrylily rhizomes, sorbus tianchanica, Chinese alangium roots, rhubarb stems, a herb of common crabgrass, Japanese metaplexis pericarp, grassleaf sweelflag rhizomes and radix asparagi. The traditional Chinese medicine composition is used for conditioning determined fundamental pathogenesis of the chronic bronchitis according to traditional Chinese medicine, and rules of treatment are clear. The traditional Chinese medicine composition is specially used for treating the chronic bronchitis, is safe in clinical application and does not stimulate internal organs after being taken. By utilizing the reasonably-compatible ingredients, the treating effect is remarkably improved, the properties of the medicinal materials are changed or moderated, and the toxicity and side effect of the medicinal materials are eliminated. A treatment period is short, the treating effect is remarkable, and clinical application study shows that the cure rate of the traditional Chinese medicine composition for treating the chronic bronchitis is up to 95%, and the total effective rate is up to 99%.
Radical resection is performed, and the cutting edge is negative, or radical local radiotherapy is feasible (cumulative radiotherapy dose is greater than or equal to 50Gy). Systemic endocrine therapy and targeted therapy are allowed after radical local therapy. However, whether systemic chemotherapy should be used is determined by clinicians according to clinical experience or guidelines.
The invention relates to palsy-removing medicinal liquor for enema treatment of rheumatoid arthritis. The palsy-removing medicinal liquor is prepared from the following medicinal raw materials by weight: 55-65g of angelica sinensis, 55-65g of ligusticum wallichii, 150-250g of astragalus membranaceus, 15-25g of radix aconiti preparata, 8-12g of prepared kusnezoff monkshood roots, 15-25g of asarum, 90-110g of radix aconiti lateralis preparata, 80-100g of cassia twig, 35-45g of agkistrodon and 55-65g of scorpio. The palsy-removing medicinal liquor which is delivered to rectum is simple to operate, noninvasive and easy to accept by patients. Medicines in rectum are absorbed faster than that by oral administration. As medicines are mixed in a rectal secretion, the medicines are easily absorbed by intestinal mucosa, so that the patient unable to swallow is particularly more suitable for being treated by administration. The rectal administration method is wide in application range, quick to take effect and reliable in curative effect. The palsy-removing medicinal liquor is used while prepared, and is free of obvious adverse effects and side effects.
After separating participants into two groups, doctors that drawed envelop number 2 will be asked to intubate with laryngoscope by using the adult size endotracheal tube introducer with using No. 3 Macintosh laryngoscope.
The invention aims to provide a traditional Chinese medicine preparation for treating ankylosing spondylitis. The traditional Chinese medicine preparation is prepared from the following raw medicinal materials (by weight): 12.0-13.8% of lantern plant calyx, 9.4-11.1% of potentilla discolor, 12.0-13.8% of lawn pennywort herb, 9.4-11.1% of monochasma sheareri maxim.ex Franch. et Savat., 6.9-9.8% of tibetan hellebore, 9.4-11.1% of caesalpinia cucullata, 9.4-11.1% of bauhinia championii, 16.3-18.1% of smilax glabra and 7.1-8.9% of honey-fried licorice root. Based on theory of traditional Chinese medicine, previous traditional formula speciality is researched and collected, and modern scientific research achievements are combined to form the clinical formula. It shows through results that the traditional Chinese medicine preparation has remarkable curative effect of treating ankylosing spondylitis diseases through compatibility of the raw medicines and the efficacy of dissolving turbidity and softening tendon and activating meridians to stop pain is effectively performed. The effective medicine has an ordered combination of ingredients, is effectively used in treating ankylosing spondylitis disease, has a good curative effect, is low-cost, and has no toxic or side effect.